Nano Targeting & Therapy Biopharma

Nano Targeting & Therapy Biopharma (NTT Biopharma) is a clinical-stage biotechnology company dedicated to the development of advanced boron-containing pharmaceuticals for Boron Neutron Capture Therapy (BNCT). The company leverages its proprietary nanoparticle and tumor-targeting technologies to deliver Boron-10 isotopes specifically to malignant cells, which then undergo a nuclear reaction upon neutron irradiation to destroy the tumor from within. Their lead candidate, NTT-001, is currently in clinical development for the treatment of recurrent head and neck cancers and glioblastoma. By focusing on high-precision drug delivery, NTT Biopharma aims to provide a more effective and less toxic alternative to traditional radiotherapy for patients with refractory solid tumors. The company is headquartered in the Hsinchu Science Park in Taiwan and collaborates closely with leading research institutions to advance the field of neutron medicine.